$ALMS

Pangali Sanam (Chief Legal Officer) sold 5,000 shares of ALUMIS INC. (ALMS) at $28.00 ($0.14M total) on 2026-07-06.

ALUMIS INC. (ALMS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001847367 0001847367 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Alumis Inc. (ALMS) shares drew three analyst price-target raises after its Q1 2026 results and progress on envudeucitinib. Chardan lifted its target to $40 from $38 (Buy), Wells Fargo to $51 from $49 (Overweight), and Guggenheim to $34 from $32 (Buy). The company reported $569.5M cash and narrowed net loss to $93.1M; envudeucitinib Week 24 PASI 90/100 results were also cited.

Deep Track Capital disclosed in a May 15, 2026 SEC filing that it bought 6,772,595 shares of Alumis (ALMS), valuing the estimated trade at $169.31 million based on the quarter’s average closing price. As of March 31, 2026, the stake was worth $149.20 million. Alumis shares were $22.02, up about 355% year over year.

Chardan Capital has reiterated its Buy rating for Alumis (ALMS.US) and increased its target price to $40. This revision suggests a strong outlook from the firm regarding Alumis's future performance.

Alumis Inc. has filed a Definitive Proxy Statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held virtually on June 30, 2026. Stockholders are asked to elect three Class II directors and ratify the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. The document details board composition, governance policies, executive and director compensation, and related person transactions, with a record date of May 5, 2026, for voting eligibility.

Deep Track Capital, Deep Track Biotechnology Master Fund, and David Kroin have jointly filed a Schedule 13G, reporting beneficial ownership of 7,362,035 shares of ALUMIS Inc. (ALMS). This represents 5.98% of the company's common stock as of April 7, 2026. The filing indicates shared voting and dispositive power over these shares, based on 123,139,425 shares outstanding as of March 12, 2026.

BML Capital Management has completely divested its stake in Alumis (NasdaqGS:ALMS), a move coinciding with Alumis's new shelf registration filing and upcoming appearances at investor conferences. This shift draws market attention to reactions from other investors as Alumis prepares for increased market engagement and potential capital-raising activities. The company's stock currently trades below analyst targets, but key risks include high volatility and unprofitability.

In the past week, significant insider buying occurred at W.R. Berkley Corp. (NYSE: WRB), Alumis Inc. (NASDAQ: ALMS), and Aktis Oncology Inc. (NASDAQ: AKTS). A beneficial owner continued to increase their stake in W.R. Berkley, while public offerings for Alumis and Aktis Oncology also attracted insider purchases. These transactions are often seen as a positive signal, as insiders typically buy shares when they anticipate a rise in stock price.

O diretor Srinivas Akkaraju da Alumis INC. adquiriu 588.235 ações ordinárias no valor de US$ 9,9 milhões a US$ 17,0 cada. Atualmente, as ações estão sendo negociadas com um prêmio de 30% e subiram 36% na última semana. A empresa também realizou uma oferta pública ampliada de US$ 345,1 milhões e recebeu feedback positivo de analistas após ensaios bem-sucedidos da Fase III para seu medicamento Envudeucitinib, levando a aumentos nos preços-alvo por Guggenheim e Oppenheimer.